Liquid biopsy is fast emerging ancillary method for the conventional tumor biopsies, established out of need to acquire most amount of molecular data about cancer with least amount of the surgical invasion. With rapid improvements in NGS technology, the liquid biopsies are projected to take key position in context of cancer related investigation and probe.
Furthermore, with expected positive results from number of clinical trials for development of these tests and following higher scaled clinical trials representative efficacy, it is expected that the testing procedure will serve broader base of patient in the molecular monitoring settings. The three most potential biofluids under enormous clinical observations for the liquid biopsy selection are urine, blood, and saliva.
Moreover, based on the form biopsy is probe into the free flowing circulating tumour cells, biomarkers utmost suited and being studied for feasible commercial development inlcude circulating tumor DNA, CTCs, and exosomes containing tumor RNA or DNA. Technologies under the R&D include the PCR-based assays for the single gene analysis and the NGS-based parallel gene analysis.Segment Overview
Implications of the complete commercialization of various liquid biopsies procedure is expected to be greatly disruptive. Three key uses of liquid biopsy can be as the therapy selection tool for the metastatic breast cancers, and for other metastatic cancers, as well as molecular health monitoring. With the growing incidence of metastatic cancer around the world, therapy selection tool for the metastatic breast cancers segment is expected to hold a substantial share in market throughout the projection period.
Once a considerable number of the liquid biopsy products are commercialized, the liquid biopsy is expected to find application not only in the cancer diagnosis, but as molecular monitoring diagnostic tool for various other diseases, that can be investigated using various biofluids such as CSF, blood, urine and saliva for the cancer recurrences, patient screening, and other associated prognosis.Regional Overview
The market for liquid biopies has been on rise in most of regions owing to the growing incidence of cancer and consequently rising need for the screening and growing competition between various biotechnology firms to enter the untapped markets around the globe. Besides these, the government grants for the research institutes to revolutionise and improve the available liquid biopsy testing approaches are expected to back the growth of market.
North America was expecting to command the major market share in 2019, followed by the Europe. The growth in the region can be accredited to the recent regulatory sanctions by CE for the commercial use of the liquid biopsy tests. On the other hand, Asia Pacific is expected to register remarkable CAGR over the forecast period as the governments and market players are trying to keep rising cancer prevalence rates in region in check. India, China, and Japan are the foremost contributing countries to the growth in the region.Competitor overview
Some of the vital players that have commercialized their tests in liquid biopsy are Biocept, Guardant Health, Trovagene, Personal Genome Diagnostics, Cynvenio, NeoGenomics Laboratories, Adaptive Biotechnologies, Qiagen, and RainDance Technologies.
Many biotech companies have started trials in China as the clinical trial regulations are reasonably lenient. Thus, inspiring the companies to shift their base from North America and Europe, where pricier trials are required for the approval and reimbursement.Key Players
- Guardant Health,
- Personal Genome Diagnostics
- Adaptive Biotechnologies
- Cynvenio, NeoGenomics Laboratories
- RainDance Technologies
- Blood Sample-based
- Urine Sample-based
- Other Bio Fluids (Tissue fluids and Saliva) based
- Therapy Selection for Metastatic Breast Cancer (MBS)
- Therapy Selection for Other Metastatic Cancer
- Molecular Health Monitoring
- North America
- Rest of Europe
- South Korea
- Rest of Asia-Pacific
- Saudi Arabia
- Rest of LAMEA